Integra LifeSciences Holdings Corporation (IART) News
Track canonical SquawkNews coverage tagged to IART, Integra LifeSciences Holdings Corporation. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 18 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
Integra LifeSciences shares are trading lower after the company announced it anticipates that flooding will disrupt Q3 revenue. The company narrowed its FY26 adjusted EPS guidance and cut its FY26 revenue.
Integra LifeSciences shares are trading lower after the company announced it anticipates that flooding will disrupt Q3 revenue. The company narrowed its FY26 adjusted EPS guidance and cut its FY26 revenue.
LIVE | Oct 02, 2026, 01:02 PM UTC
H
Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B
Integra LifeSciences Holdings Corporation (Nasdaq: IART ), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance. Bas
LIVE | Oct 02, 2026, 12:09 PM UTC
M
Integra LifeSciences posts preliminary Q3 results, updates 2026 guidance
Integra LifeSciences announced preliminary third-quarter results and updated full-year 2026 guidance.
EQUITY | Oct 02, 2026, 12:05 PM UTC
L
Integra LifeSciences Announces 100th Patient Enrolled in AERA® Pediatric Registry
Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patientsACCLARENT AERA® Eustachian Tube Balloon Dilation SystemPRINCETON, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeScience
NEWS | Sep 29, 2026, 12:32 PM UTC
H
Integra LifeSciences Marks 20 Years of CUSA® Technology with Liver Surgery Education at ACS Clinical Congress 2026
Company to feature surgeon-led educational programming and technologies supporting liver surgeryCUSA MicroFrancePRINCETON, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences NASDAQ:IART will mark 20 years of C
GEOPOLITICS | Sep 25, 2026, 01:08 PM UTC
L
IART sees margin expansion and innovation support through 2027
EARNINGS | Sep 09, 2026, 07:54 PM UTC
L
Integra LifeSciences updates investor presentation on remediation progress
Integra LifeSciences furnished an updated investor presentation covering remediation progress, Braintree facility start-up and LTM Q2 2026 financials.
REGULATION | Sep 08, 2026, 10:34 AM UTC
L
Integra LifeSciences CFO and CCO to present at 2026 healthcare conferences
Integra LifeSciences said Lea Knight (chief financial officer) and Michael McBreen (chief commercial officer) will present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference.
EQUITY | Sep 04, 2026, 01:17 PM UTC
L
IART - Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference - Cli
IART - Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
EQUITY | Sep 04, 2026, 01:15 PM UTC
L
IART Integra Lifesciences RESULTS: Q2, Q2 ADJ Net Income $43.7M, Q2 ADJ EPS $0.56 vs. EST $0.48, Q2 ADJ EBITDA $78.4M, Q2 EPS $0.06, Q2 REV
IART Integra Lifesciences RESULTS: Q2, Q2 ADJ Net Income $43.7M, Q2 ADJ EPS $0.56 vs. EST $0.48, Q2 ADJ EBITDA $78.4M, Q2 EPS $0.06, Q2 REV $418.8M vs. EST $418.6M, Integra Lifesciences Earnings Notes:, Integra Lifescien
EARNINGS | Jul 29, 2026, 10:24 AM UTC
L
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.65
Integra Lifesciences (NASDAQ: IART ) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654 billion-$1.695 bill
EARNINGS | Jul 29, 2026, 10:08 AM UTC
L
IART - Integra LifeSciences Reports Second Quarter 2026 Financial Results
IART - Integra LifeSciences Reports Second Quarter 2026 Financial Results
EARNINGS | Jul 29, 2026, 10:00 AM UTC
L
IART new Neutral W/ $19 PT @ UBS
IART new Neutral W/ $19 PT @ UBS
EQUITY | Jul 28, 2026, 12:46 PM UTC
L
IART Initiated Neutral W/$19.00 PT at UBS
IART Initiated Neutral W/$19.00 PT at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
H
BMO starts 'show-me story' Integra LifeSciences with a Market Perform
As previously reported, BMO Capital initiated coverage of Integra LifeSciences with a Market Perform rating and $19 price target. While early signs of recovery - including a Q1 beat and record Integra Skin production - a
EARNINGS | Jul 08, 2026, 08:34 PM UTC
H
Integra LifeSciences price target raised to $19 from $16 at Citi
Citi raised the firm's price target on Integra LifeSciences to $19 from $16 and keeps a Neutral rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medt
EQUITY | Jul 08, 2026, 10:36 AM UTC
L
IART Appoints Executives
Integra LifeSciences announces key executive appointments to enhance commercial execution and customer engagement
EQUITY | Jun 23, 2026, 12:01 PM UTC